Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) have been given a consensus rating of "Moderate Buy" by the ten analysts that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $24.13.

Several research firms have commented on RCUS. Barclays dropped their target price on shares of Arcus Biosciences from $29.00 to $14.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 23rd. HC Wainwright raised shares of Arcus Biosciences from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $18.00 to $24.00 in a research report on Wednesday, February 26th. Wells Fargo & Company dropped their target price on shares of Arcus Biosciences from $29.00 to $26.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. Wedbush reissued an "outperform" rating and set a $33.00 target price on shares of Arcus Biosciences in a research report on Wednesday, May 7th. Finally, Morgan Stanley dropped their target price on shares of Arcus Biosciences from $24.00 to $22.00 and set an "overweight" rating on the stock in a research report on Friday, May 9th.

Institutional Investors Weigh In On Arcus Biosciences

A number of hedge funds have recently modified their holdings of the stock. Gilead Sciences Inc. raised its holdings in shares of Arcus Biosciences by 4.5% in the 1st quarter. Gilead Sciences Inc. now owns 31,424,760 shares of the company's stock worth $246,684,000 after purchasing an additional 1,363,636 shares during the period. Vanguard Group Inc. raised its holdings in shares of Arcus Biosciences by 24.1% in the 1st quarter. Vanguard Group Inc. now owns 6,687,800 shares of the company's stock worth $52,499,000 after purchasing an additional 1,298,584 shares during the period. Woodline Partners LP raised its holdings in shares of Arcus Biosciences by 45.5% in the 1st quarter. Woodline Partners LP now owns 5,127,304 shares of the company's stock worth $40,249,000 after purchasing an additional 1,603,367 shares during the period. Dimensional Fund Advisors LP raised its holdings in Arcus Biosciences by 11.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,702,302 shares of the company's stock valued at $25,348,000 after acquiring an additional 178,351 shares during the period. Finally, Boxer Capital Management LLC bought a new stake in Arcus Biosciences during the 4th quarter valued at $23,857,000. Institutional investors own 92.89% of the company's stock.

Arcus Biosciences Price Performance

RCUS stock opened at $8.67 on Monday. The company has a market capitalization of $917.54 million, a P/E ratio of -2.07 and a beta of 0.83. The company has a debt-to-equity ratio of 0.09, a quick ratio of 5.37 and a current ratio of 5.37. Arcus Biosciences has a 52-week low of $6.50 and a 52-week high of $18.98. The business has a 50-day simple moving average of $8.74 and a two-hundred day simple moving average of $10.93.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.12). Arcus Biosciences had a negative return on equity of 70.58% and a negative net margin of 258.94%. The firm had revenue of $28.00 million for the quarter, compared to the consensus estimate of $38.61 million. During the same period in the prior year, the business earned ($0.05) EPS. Arcus Biosciences's quarterly revenue was down 80.7% compared to the same quarter last year. Research analysts expect that Arcus Biosciences will post -3.15 EPS for the current fiscal year.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.